|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cryptocurrency News Articles
HBAR Has Recorded a 7% Drop over the Past Week, Underperforming the Broader Crypto Market
May 06, 2025 at 08:26 pm

HBAR, the native token of Hedera, has encountered a setback in its recovery, slipping by 7% over the past week. This underperformance is in contrast to the broader crypto market, which has shown signs of a mild rebound.
A closer look at the technicals paints a bleak picture, with key indicators suggesting the selloff may continue in the short term.
HBAR Bulls Step Back as Sellers Gain Ground
An assessment of the HBAR/USD one-day chart shows that the token’s Relative Strength Index (RSI) remains below the neutral 50 level and continues to trend downward. As of this writing, this momentum indicator is at 43.38.
The Relative Strength Index (RSI) is a momentum indicator used to assess whether an asset is overbought or oversold. It operates on a scale from 0 to 100, with readings above 70 typically signaling overbought conditions and a potential price correction. On the other hand, values below 30 suggest the asset is oversold and may be poised for a rebound.
HBAR’s RSI reading signals growing bearish momentum. Its weakening value suggests that selling pressure is intensifying, reducing the likelihood of a short-term rebound.
HBAR’s Balance of Power (BoP) indicator, which currently returns a negative value of -0.27 at press time, further reinforces the bearish outlook.
This indicator measures the strength of buyers versus sellers by analyzing price movement within a given period. When an asset’s BoP is negative, it indicates that sellers are dominating the market. This increases the likelihood of continued downward pressure on HBAR’s price in the short term.
HBAR Faces Downtrend Pressure
HBAR’s decline over the past days has caused it to trade below a descending trend line. This is a bearish pattern formed when an asset consistently makes lower highs over time, and those highs can be connected by a straight line sloping downward.
The longer the trend line holds, the stronger the indication that the asset is in a sustained downtrend. This pattern reflects a bearish market sentiment, where HBAR sellers gradually overpower buyers.
If this continues, it could push HBAR’s price further to $0.12.
However, a rally above the descending trend line could propel the HBAR token’s price to $0.19.
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
-
- Datavecta Forges Global Community Ecosystem to Power International Growth Through Advanced SEO Strategy
- Sep 30, 2026 at 07:55 pm
- Datavecta is building a global community ecosystem to enhance international growth, leveraging advanced SEO strategies and technology-driven services for a connected intelligent trading future.
-
- Illinois Rolls Out Draft Rules for 0.2% Crypto Transaction Tax, Set for 2027
- Sep 30, 2026 at 12:05 pm
- Illinois unveils draft regulations for its upcoming 0.2% digital asset transaction tax, impacting exchanges, transfers, and custody services starting January 1, 2027. The tax applies to the gross value of transactions, not investment gains.
-
-
- Apeing Leads the Charge: Unveiling the Next 100x Crypto Watchlist and 6 Coins to Eye
- Sep 30, 2026 at 12:03 pm
- Amidst a dynamic crypto market, Apeing's presale momentum, coupled with established players like Solana and TRON, is redefining the 100x crypto narrative, offering both early-stage opportunities and proven network strength.
-
-
- OpenAI Unveils GPT-6.1 Sol and Ultrafast Tier, While AstraZeneca Invests Big in Summit Therapeutics
- Sep 30, 2026 at 08:05 am
- OpenAI rolls out GPT-6.1 Sol, offering near-Astra performance at a fraction of the cost, alongside a new 'Ultrafast' speed tier. Meanwhile, AstraZeneca makes a significant $2 billion investment in oncology firm Summit Therapeutics.
-
-
































